Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H26N6O2 |
Molecular Weight | 394.4701 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=C(CNCC2CCN(CC2)C3=NC=C(C=N3)C(=O)NO)C4=C1C=CC=C4
InChI
InChIKey=PAWIYAYFNXQGAP-UHFFFAOYSA-N
InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)
Quisinostat is an orally bioavailable potent histone deacetylase inhibitor, specifically selected due to its sustained inhibition of HDAC1 in solid tumor tissues and prolonged period of half-elimination from tissues. Phase 2 clinical trials are ongoing in patients with platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Quisinostat is active in the treatment of patients with relapsed or refractory Sézary syndrome. The most common drug-related adverse events reported in this trial were: nausea, diarrhea, asthenia. Grade 3 adverse events were also reported: hypertension, lethargy and pruritus.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL325 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19861438 |
0.11 nM [IC50] | ||
Target ID: CHEMBL1937 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19861438 |
0.33 nM [IC50] | ||
Target ID: CHEMBL3310 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19861438 |
0.37 nM [IC50] | ||
Target ID: CHEMBL5103 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19861438 |
0.46 nM [IC50] | ||
Target ID: CHEMBL3524 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19861438 |
0.64 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01486277
12 mg capsule on days 1, 3, and 5 of each week in a 21-day treatment cycle
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19861438
Quisinostat inhibited cell proliferation in all lung, breast, colon, prostate, brain, and ovarian tumor cell lines tested, with IC50 values ranging from 3.1 to 246 nM/L.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1946
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C77912
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY | |||
|
9BJ85K1J8S
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105763
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY | |||
|
Quisinostat
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY | |||
|
9452
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY | |||
|
DTXSID90236376
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY | |||
|
DB12985
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY | |||
|
100000166929
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY | |||
|
875320-29-9
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY | |||
|
SUB181224
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY | |||
|
11538455
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY | |||
|
XX-125
Created by
admin on Sat Dec 16 01:40:29 GMT 2023 , Edited by admin on Sat Dec 16 01:40:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)